The PD-1/PD-L1 blockade is intended to reinvigorate exhausted tumor-specific CD8 + T-cells, and the expression of CD8 + T cells is required for therapeutic response (Kurtulus et al., 2019). This evidence concerns the gene CD8A and neoplasm.